CWBR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 13:54):

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases...

Stats
Today's Volume	358.00
Average Volume	2 198.00
Market Cap	2.33M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.180
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-01	Biunno Jeffrey Francis	Buy	26 203	Common Stock
2022-08-01	Sarret Joseph J.	Buy	131 017	Common Stock
2022-07-11	Tozzo Stephanie	Buy	200 000	Stock Option (Right to buy)
2022-07-11	Tozzo Stephanie	Buy	0
2021-12-29	Biunno Jeffrey Francis	Buy	75 000	Stock Option (Right to buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 7 451 858 \| Sell: 253 700

CohBar Inc Correlation

10 Most Positive Correlations
YJ	0.911
EFOI	0.867
PRVB	0.865
SMED	0.863
CXSE	0.859
PXLW	0.857
HLBZ	0.856
PCTTU	0.849
MCHI	0.848
WB	0.839

10 Most Negative Correlations
HZNP	-0.876
PPBT	-0.834
SLGG	-0.829
LEDS	-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CohBar Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-4.13

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.490

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.700

Q4	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.270

Financial Reports:

No articles found.

CohBar Inc

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.